Guidelines for Prevention and Treatment of Chronic Hepatitis B

来源 :临床与转化肝病杂志(英文版) | 被引量 : 0次 | 上传用户:yp7611
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
To achieve the goal of the World Health Organization to eliminate viral hepatitis as a major public health threat by 2030, the Chinese Society of Infectious Diseases and the Chinese Society of Hepatology convened an expert panel in 2019 to update the guidelines for the prevention and treat-ment of chronic hepatitis B (CHB). The current guidelines cover recent advances in basic, clinical, and preventive studies of CHB infection and consider the actual situation in China. These guidelines are intended to provide support for the prevention, diagnosis, and treatment of CHB.
其他文献
The diagnosis of metabolic-associated fatty liver disease is based on the detection of liver steatosis together with the presence of metabolic dysfunction. According to this new defi-nition, the diagnosis of metabolic-associated fatty liver disease is ind
Nonalcoholic fatty liver disease (NAFLD) affects about a quar-ter of the world\'s population and poses a major health and economic burden globally. Recently, there have been hasty attempts to rename NAFLD to metabolic-associated fatty liv-er disease (MA
Metabolic dysfunction-associated fatty liver disease (com-monly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and eco-nomic burden is enormous. While much attention has been given to metabolic syndro
Background and Aims: The efficacy of targeted pro-grammed cell death 1/programmed death ligand 1 (PD-1/PD-L1) monoclonal antibodies (mAbs) has been confirmed in many solid malignant tumors. The overexpression of PD-1/PD-L1 serves as a biomarker to predict
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is currently the most common chronic liver disease and affects at least a quarter of the global adult population. It has rapidly become one of the leading causes of hepa-tocellular carcinoma a
Background and Aims: Exertional heatstroke (EHS) is as-sociated with strenuous physical activity in hot environments. The present study aimed to investigate dynamic changes of hepatic function indices in EHS patients and determine risk factors for death.
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new term from nonalcoholic fatty liver disease (NAFLD) and is a positive diagnosis based on histopathology, imaging, or blood biomarkers. MAFLD is one of the common causes of liver dysfunct
Hepatic encephalopathy is an often devastating complication of chronic liver disease, associated with high mortality and in-creased burden on patients and healthcare systems. Current agents (such as nonabsorbable disaccharides and oral anti-biotics) are o
Hepatocellular carcinoma (HCC) is one of the leading caus-es of cancer deaths worldwide and liver transplantation (LT) is the only potentially curative treatment. Over the years, Milan criteria has been used for patient selection. There is ongoing researc
The liver is frequently affected by severe acute respira-tory syndrome-coronavirus 2 (SARS-CoV-2) infection. The most common manifestations are mildly elevated alanine aminotransferase and aspartate aminotransferase, with a prevalence of 16-53% among pati